Maria Kristina Wigenfeldt

Quantovir AB conducts research and development of methods for cancer diagnostics and related business. It develops technology for quantitative measurement of high-risk Human Papillomavirus (HPV) types using deoxyribonucleic acid (DNA)-based detection. It demonstrates that a molecular diagnostic test measuring the quantity, or viral load, of HPV DNA present in cervical specimens can be used to predict a woman's risk of developing cervical cancer. The company was founded by Ulf Gyllensten on February 28, 2001 and is headquartered in Uppsala, Sweden.

Quantovir AB conducts research and development of methods for cancer diagnostics and related business. It develops technology for quantitative measurement of high-risk Human Papillomavirus (HPV) types using deoxyribonucleic acid (DNA)-based detection. It demonstrates that a molecular diagnostic test measuring the quantity, or viral load, of HPV DNA present in cervical specimens can be used to predict a woman's risk of developing cervical cancer. The company was founded by Ulf Gyllensten on February 28, 2001 and is headquartered in Uppsala, Sweden.